Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization

NCT03702244 is registered in ClinicalTrials.gov with HeartFlow, Inc. as lead sponsor.

NCT NCT03702244
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03702244 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization
Lead sponsor
HeartFlow, Inc.
Phase
Not applicable
Overall status
Completed
Start date
November 27, 2018
Completion date
May 20, 2022
Enrollment
2,103 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

coronary artery disease